N-Acetylcysteine in Patients With Sickle Cell Disease

Sickle Cell Disease Clinical Trial

— NAC  

Official title:

N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01849016
• Other study ID #: NAC trial
• Secondary ID: 2012-004892-3717
• Status: Completed
• Phase: Phase 3
• First received: May 6, 2013
• Last updated: June 30, 2016
• Start date: April 2013
• Est. completion date: June 2016

Study information

• Verified date: June 2016
• Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Dutch Health Care InspectorateNetherlands: Medical Ethics Review Committee (METC)Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The primary aim of this study is to evaluate the effect of the drug N-Acetylcysteine on the frequency of pain in daily life in patients with Sickle Cell Disease (SCD).

Pain is an invalidating hallmark of this disease and has a considerable impact on the Quality of Life of patients and the medical health care system. Oxidative stress is hypothesized to play a central role in its pathophysiology. In pilot studies the administration of N-Acetylcysteine (NAC) resulted in a reduction of oxidative stress. Moreover, administration of NAC seemed to decrease hospitalization for painful crises in a small pilot study in patients with SCD.

This study will be performed as a multicenter, randomized, controlled trial where patients will be treated with either NAC or placebo for a period of 6 months. The investigators expect that NAC can reduce the frequency of pain in patients with SCD, thereby improving their quality of life and participation in society.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Age 12 years or older

• Sickle cell disease, either homozygous sickle cell disease (HbSS), compound heterozygous sickle cell disease (HbSC), HbSß0 or HbSß+ thalassemia

• History of at least 1.0 painful crisis per year in the past 3 years (visit to medical facility is not required)

Exclusion Criteria:

• Chronic blood transfusion or transfusion in the preceding 3 months

• Painful crisis in the last 4 weeks (with respect to the moment of inclusion)

• Pregnancy, breast feeding or the desire to get pregnant in the following 7 months

• Known active gastric/duodenal ulcers

• Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or started on HC shorter then 6 months prior to study

• Known poor compliance in earlier trials regarding the completion of pain diaries

• Insufficient compliance in run-in period

• Known hypersensitivity to acetylcysteine or one of the other components of the study medication

• Use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months ('chronic pain').

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• N-Acetylcysteine

• Placebo

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels
Belgium	CHU St. Pierre	Brussels
Belgium	Hôpital Erasme	Brussels
Belgium	Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF)	Brussels
Belgium	UCL St. Luc	Brussels
Belgium	CHR de la Citadelle	Liège
Netherlands	Academic Medical Center	Amsterdam
Netherlands	University Medical Center Groningen	Groningen
Netherlands	Erasmus Medical Center	Rotterdam
Netherlands	Haga Hospital	The Hague
United Kingdom	Guys' & St. Thomas Hospital	London

Sponsors (14)

Lead Sponsor

Collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Centre Hospitalier Régional de la Citadelle, Centre Hospitalier Universitaire Saint Pierre, CHU Brugmann, Brussels, Erasme University Hospital, Erasmus Medical Center, Fonds NutsOhra, Guy's and St Thomas' NHS Foundation Trust, Haga Hospital, Queen Fabiola Children's University Hospital, Stichting Janivo, University Hospital St Luc, Brussels, University Medical Center Groningen, ZonMw: The Netherlands Organisation for Health Research and Development

Countries where clinical trial is conducted

Belgium,  Netherlands,  United Kingdom, 

References & Publications (8)

Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ; CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011 Jun;86(6):484-9. doi: 10.1002/ajh.22012. Epub 2011 May 4. Review. — View Citation

Nur E, Brandjes DP, Schnog JJ, Otten HM, Fijnvandraat K, Schalkwijk CG, Biemond BJ; CURAMA Study Group. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br J Haematol. 2010 Oct;151(1):62-9. doi: 10.1111/j.1365-2141.2010.08320.x. Epub 2010 Jul 30. — View Citation

Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RP, Muskiet F, Evers LM, ten Cate H, Biemond BJ, Duits AJ, Schnog JJ; CURAMA study group. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012 Jul;91(7):1097-105. doi: 10.1007/s00277-011-1404-z. Epub 2012 Feb 10. — View Citation

Nur E, Verwijs M, de Waart DR, Schnog JJ, Otten HM, Brandjes DP, Biemond BJ, Elferink RP; CURAMA Study Group. Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. Biochim Biophys Acta. 2011 Nov;1812(11):1412-7. doi: 10.1016/j.bbadis.2011.04.011. Epub 2011 May 3. — View Citation

Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol. 2003 May;73(1):26-32. — View Citation

Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94-101. — View Citation

Somjee SS, Warrier RP, Thomson JL, Ory-Ascani J, Hempe JM. Advanced glycation end-products in sickle cell anaemia. Br J Haematol. 2005 Jan;128(1):112-8. — View Citation

van Tuijn CF, van Beers EJ, Schnog JJ, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol. 2010 Jul;85(7):532-5. doi: 10.1002/ajh.21731. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence rate of SCD related pain in daily life per patient year	The incidence of pain in daily life will be expressed as the number of pain days in relation to total follow-up time, and transformed to an event rate per patient year with a corresponding rate ratio and its 95% confidence interval.; A pain day will be defined as: When the box "Yes, I have experienced pain" is checked in the daily pain diary.; Days with hospital admission for painful crisis will be included in the total number of pain days and in the total number of diary observation days, irrespective of pain diary reports on these dates.	6 months	No
Secondary	The severity of SCD related pain in daily life, using a 0-10 numerical rating scale (NRS) in the study pain diary.	The average intensity of pain indicated on pain days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all pain days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution.	6 months	No
Secondary	The incidence rate per patient year of painful crises (episodes, based on pain diary observation)	The number of patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Also, the average number of crisis days per patient in relation to total follow-up time will be evaluated (including hospital admission days, see below).; A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary.; Missing diary days that are immediately preceded and followed by crisis days or by hospital admission.; A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics.; An acute chest syndrome	6 months	No
Secondary	The incidence rate per patient year of days with painful crises (days, based on pain diary observation)	The number of days with patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.; A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary.; Missing diary days that are immediately preceded and followed by crisis days or by hospital admission.; A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics.; An acute chest syndrome	6 months	No
Secondary	The severity of painful crises. This will be defined using a 0-10 numerical rating scale (NRS) in the pain diary.	The average intensity of pain indicated on crisis days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all crisis days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution.; Painful crisis definition as above.	6 months	No
Secondary	The incidence rate per patient year of hospital admissions	The number of sickle cell related hospital admissions in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.; Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.	6 months	No
Secondary	The incidence rate per patient year of hospital admission days	The number of sickle cell related hospital admission days in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.; Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.	6 months	No
Secondary	Time in days to first painful crisis (as defined above)	The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.	6 months	No
Secondary	Time in days to first hospital admission for painful crisis (as defined above)	The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.	6 months	No
Secondary	The health-related Quality of Life, as measured by use of validated questionnaires.	In adults this will be assessed with SF36-forms, a short-form health survey that has been proven to be valid and reliable in the black population.46 In children from 12 to 18 years old, we will use the PedsQL questionnaire, often used to assess quality of life in children, also validated in SCD patients	6 months	No
Secondary	The SCD-related societal costs, assessed by a prospective cost-effectiveness analysis	The societal costs of pain care with the use of NAC, in the intervention group, will be compared to the societal costs of current pain care in the control group. Estimates of unit costs will be based on calculation of real costs of pain care.; Generated direct medical costs will be recorded in the case record forms and by means of the Medical Cost Questionnaire (see appendix). Indirect costs arising from losses in productivity will be assessed by means of the Productivity Cost Questionnaire (see appendix) and will be calculated by means of the friction cost method.	6 months	No
Secondary	The tolerability of NAC, defined as the number of participants with adverse events.	This will be assessed via the monthly adverse events reports. The frequency of registered adverse events and/or a serious adverse events will be reported per treatment arm, and compared between the two intervention groups.	6 months	Yes
Secondary	The incidence rate per patient year of use of home pain medication (based on pain diary observation). This information will be recorded by subjects in their daily pain diary, including type and dosage of pain medication.	The incidence rate of analgesic usage will be defined as the proportion of pain days with reported analgesic use on the total number of pain days (excluding observation days with no reported pain). This proportion will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.	6 months	No
Secondary	Incidence of SCD complications.	The number of patients with sickle cell related complications (i.e. acute chest syndrome, stroke etc.) will be reported per treatment arm, and compared between the two intervention groups.; The related incidence of SCD complications; Acute chest syndrome; Priapism; Hepatic sequestration; Splenic sequestration; Cerebrovascular accident; Leg ulcer; Symptomatic avascular osteonecrosis; These complications will be assessed monthly by using hospital medical records.	6 months	No
Secondary	The changes in blood markers of oxidative stress, hemolysis, hypercoagulability, inflammation, erythrocyte adhesion and endothelial dysfunction		6 months	No
Secondary	Compliance of study medication; proportion of study medication used based on pill counts.	Compliance of use of study medication will primarily be checked by pill counts (number administered versus number returned). Compliance will be expressed as the proportion of tablets remaining, compared to the number of tablets that should have been taken based on a prescription of 2 tablets per day and the total number of observation days per patient.	6 months	No
Secondary	Compliance of study medication; N-acetylcysteine plasma concentrations	We additionally aim to evaluate compliance by N-acetylcysteine plasma concentration measurements in blood samples drawn at T0, T3 and T6 in the intervention group, and assess mean change from baseline in the intervention group. This outcome may be used as alternative parameter for patient compliance if pill counts do not suffice.	6 months	No